# A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

> **NCT07214662** · PHASE1 · RECRUITING · sponsor: **Genentech, Inc.** · enrollment: 136 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** GDC-0587
- **DRUG:** Giredestrant
- **DRUG:** Omeprazole

## Key facts

- **NCT ID:** NCT07214662
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-13
- **Primary completion:** 2030-06-01
- **Final completion:** 2030-06-01
- **Target enrollment:** 136 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07214662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07214662, "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07214662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*